Who
Gary Bridger
Director
Company insider
Files Form 4 as: Director, X4 Pharmaceuticals; Director, Neurogene; Director, Alder Biopharmaceuticals; EVP, Research & Development, Xenon Pharmaceuticals.
In numbers
- Trades disclosed
- 52
- Buys
- 1
- Sells
- 0
- Bought
- $2.5M
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 6 Mar 2014
- Last trade
- 1 Jan 2026
- Last filed
- 7 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jan 2026filed 7 Jan 2026 | XFOR X4 Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 1 Jan 2026filed 7 Jan 2026 | XFOR X4 Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 9 Jun 2025filed 10 Jun 2025 | XFOR X4 PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —1,500 at $0.00 | filing |
| 10 Jun 2024filed 11 Jun 2024 | XFOR X4 PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 13 Jun 2023filed 14 Jun 2023 | XFOR X4 PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 6 Jun 2022filed 27 Jun 2022 | XFOR X4 PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —6,667 at $0.00 | filing |
| 2 Jun 2021filed 2 Jun 2021 | XFOR X4 Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $57K6,000 at $9.50 | filing |
| 5 Oct 2020filed 6 Oct 2020 | XFOR X4 Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 10 Jun 2020filed 11 Jun 2020 | XFOR X4 Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,427 at $0.00 | filing |
| 13 Mar 2019filed 2 Apr 2019 | XFOR X4 Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,570 | filing |
| 13 Mar 2019filed 2 Apr 2019 | XFOR X4 Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,854 at $0.00 | filing |
| 13 Mar 2019filed 14 Mar 2019 | XFOR X4 Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,570 | filing |
| 7 May 2018filed 9 May 2018 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 8 May 2017filed 10 May 2017 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,000 at $0.00 | filing |
| 9 May 2016filed 11 May 2016 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 31 Oct 2015filed 3 Nov 2015 | NGNE NeurogeneBiotechnology | SEC FORM 4 Code J | —1,543,989 at $0.00 | filing |
| 31 Oct 2015filed 3 Nov 2015 | Alder Biopharmaceuticals | SEC FORM 4 Code J | —3,469,528 at $0.00 | filing |
| 19 May 2015filed 21 May 2015 | Alder Biopharmaceuticalsoption or derivative | SEC FORM 4 Code A | —6,350 at $0.00 | filing |
| 12 Mar 2015filed 16 Mar 2015 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 21 Nov 2014filed 25 Nov 2014 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,144 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.